The latest research: Wegovy is also effective for patients with diabetes and heart failure
嫦娥的情人矩
发表于 2024-4-7 10:32:07
1253
0
0
A new study shows that Wegovy (mainly composed of smeglutide), the "weight-loss magic drug" of Novo Nordisk, can not only lose weight, but also benefit the health of patients with diabetes and heart failure.
This report, published on Saturday (April 6th) in the medical journal New England Journal of Medicine, stated that for heart failure patients, especially those with preserved ejection fraction (HFpEF) associated with obesity, receiving Wegovy treatment resulted in more significant weight loss and lower incidence of serious adverse events.
This type of heart failure severely limits a person's ability to participate in daily life, and patients are often prone to fatigue, breathing difficulties, which can lead to a high risk of hospitalization, disability, and death.
At present, the methods for treating HFpEF include lifestyle changes and heart disease drugs, but there is no specifically approved treatment for HFpEF, and the number of people suffering from this disease has been significantly increasing.
Last fall, researchers released a study that showed that Wegovy had a significant positive health effect on people with this heart disease, but later they wanted to see whether Wegovy also had an effect on patients with type 2 diabetes and HFpEF.
In the latest study, 616 patients with type 2 diabetes and HFpEF were randomly divided into two groups. The patients come from 16 countries and their body mass index (BMI) is above 30. One group takes Wegovy, and the other group takes a placebo.
Researchers conducted a one-year follow-up survey on two groups of patients. The conclusion is that patients receiving Wegovy treatment have significantly better effects on weight loss, heart failure related symptoms, and physical limitations compared to those taking placebo. In addition, these patients were able to walk further in the six minute walk test and showed improvement in biomarkers for inflammation and other issues.
In terms of adverse events, the Wegovy treatment group reported 55 severe adverse events, while the placebo group reported 88 cases. In terms of the number of deaths, there were 6 deaths in the Wegovy group and 10 deaths in the placebo group, with 1 death related to cardiovascular problems in the Wegovy group and 4 deaths in the placebo group.
Dr. Mikhail Kosiborod, a researcher and cardiologist at the Central American Heart Institute in Saint Luke, said that the consistent results of the latest research and the research published last year seemed to indicate that Wegovy was an effective and safe treatment option for a wide range of people, including diabetes patients.
On Saturday, Kosiborod also introduced the study to the American College of Cardiology, and he found it very exciting because heart failure patients are usually difficult to treat, and the number of such patients is constantly increasing. But now, Wegovy has not only shown therapeutic efficacy, but also good tolerability, which means patients can withstand this treatment well without serious side effects.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Smeaglutide tablet for type 2 diabetes was approved for marketing in China
- Oral smeglutide is approved to be marketed in China for the treatment of type 2 diabetes
- Li Xiande from Jingke Energy: Maintain strategic patience during the industry's lowest period of downturn. Unprofitable production capacity will be quickly phased out
- Federal Reserve Governor Waller: Stay patient with interest rate cuts, wait for more data!
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Abbott: Science and technology enable daily management of diabetes, stable and accurate, and protect blood sugar health
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏